aciclovir
Hematopoietic and Lymphoid Cell Neoplasm
Children's Oncology GroupSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
80 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
DEXAMETHASONE Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 2 | BB |
Pegloticase M.D. Anderson Cancer Center | Phase 4 | BB |
Monomethyl Fumarate Fred Hutchinson Cancer Center | Phase 3 | BB |
View all 50 →
Same molecule, other indications
aciclovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →